Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| HHSN275201000003I/27500051 | Other Grant/Funding Number | NICHD |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| The Emmes Company, LLC | INDUSTRY |
| Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | NIH |
Not provided
Not provided
Not provided
Over half of women in the US who are breastfeeding their infants take prescription drugs. You are being asked to participate in this study because you are breastfeeding your infant and are currently taking, as part of your medical care, at least one of the drugs we are studying. We are interested in studying drugs commonly prescribed to women who are breastfeeding so we can learn more about the amount of drug that is transferred to breastmilk and estimate how much of drug that is consumed by breastfed infants.
The purpose of this study is to understand if the study drugs of interest are found in breastmilk and how much; to estimate the amount of drug that is consumed by breastfed infants and what effect this may have on infants; and to share what we learn with other researchers. The study drugs of interest have Food and Drug Administration (FDA) approval, but there is little or no information about the amount of drug found in the breastmilk of mothers who take them; the amount of drug that may be transferred to their infant's through breastmilk; or the effects this transfer may have on their infants. During this study we will ask to collect breastmilk and blood from mothers, and blood from infants, to measure the amount of study drug of interest in these body fluids. Results from this study will help researchers better understand how much of the study drug of interest is in your blood and breastmilk, and how much of the study drug of interest may be in your infant's blood because of breastfeeding.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Tranexamic acid (TXA) | No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women. The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose. |
| |
| labetalol | No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women. The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose. |
| |
| metformin | No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women. The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose. |
| |
| nifedipine | No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women. The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose. |
| |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Tranexamic acid (TXA) | Drug | Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider. |
|
| Measure | Description | Time Frame |
|---|---|---|
| M/P ratio | Characterize the pharmacokinetics using maternal milk/plasma exposure ratio is calculated by dividing the BMS01 drug of interest breastmilk concentration by the BMS01 drug of interest in maternal plasma concentration. | Until the infant becomes 180 days of age |
| DID | Pharmacokinetics is characterized by estimated daily infant dose-daily infant dose which estimates the quantity of drug delivered to an infant via breastmilk in a given day. | Until the infant becomes 180 days of age |
| RID | Pharmacokinetics is characterized by relative infant dose is a method of relating the potential dose of the drug delivered to the infant to the typical therapeutic dose given to the mother. | Until the infant becomes 180 days of age |
| I/M ratio | Pharmacokinetics is characterized using infant maternal/exposure ratio. IM ratio is calculated using the average infant plasma concentration of the BMS01 drug of interest and historical value of clearance in infants. | Until the infant becomes 180 days of age |
| Measure | Description | Time Frame |
|---|---|---|
| Safety profile of commonly used drugs in infants exposed to drugs in breastmilk | see Cohort 1-31 for listing of drugs | Until the infant becomes 180 days of age |
| AE | Safety profile of commonly used drugs in infants exposed to drugs in breastmilk is characterized by Adverse Events(AE) which are collected at each time point when the study-specific procedure occurred and up until 1 hour after. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Lactating women receiving DOIs per SOC, as prescribed by their healthcare providers, and their breastfed infants.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Emily Forgey | Contact | 919-660-8720 | emily.forgey@duke.edu | |
| Cheryl Alderman | Contact | 919-966-8349 | cheryl.alderman@duke.edu |
| Name | Affiliation | Role |
|---|---|---|
| Samia Aleem, MD | Duke University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of California-San Diego Medical Center | Recruiting | La Jolla | California | 92093 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 35076931 | Derived | Job KM, Dallmann A, Parry S, Saade G, Haas DM, Hughes B, Berens P, Chen JY, Fu C, Humphrey K, Hornik C, Balevic S, Zimmerman K, Watt K. Development of a Generic Physiologically-Based Pharmacokinetic Model for Lactation and Prediction of Maternal and Infant Exposure to Ondansetron via Breast Milk. Clin Pharmacol Ther. 2022 May;111(5):1111-1120. doi: 10.1002/cpt.2530. Epub 2022 Mar 5. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Leftover specimens will be sent to NICHD repository for unknown future use
| clindamycin |
No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women. The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose. |
|
| oxycodone | No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women. The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose. |
|
| azithromycin | No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women. The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose. |
|
| escitalopram | No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women. The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose. |
|
| sertraline | No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women. The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose. |
|
| ondansetron | No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women. The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose. |
|
| Ciprofloxacin | No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women. The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose. |
|
| Doxycycline | No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women. The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose. |
|
| Levofloxacin | No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women. The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose. |
|
| Methylphenidate | No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women. The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose. |
|
| Sumatriptan | No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women. The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose. |
|
| Citalopram | No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women. The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose. |
|
| Cyclobenzaprine | No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women. The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose. |
|
| Furosemide | No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women. The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose. |
|
| Gabapentin | No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women. The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose. |
|
| Hydrochlorothiazide | No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women. The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose. |
|
| Hydroxyurea | No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women. The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose. |
|
| Rosuvastatin | No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women. The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose. |
|
| Topiramate | No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women. The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose. |
|
| Trazodone | No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women. The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose. |
|
| Valganciclovir | No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women. The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose. |
|
| Venlafaxine | No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women. The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose. |
|
| Verapamil | No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women. The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose. |
|
| Remdesivir | No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women. The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose. |
|
| Anakinra | No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women. The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose. |
|
| Tocilizumab | No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women. The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose. |
|
| Fluvoxamine | No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women. The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose. |
|
| Amoxicillin | No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women. The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose. |
|
| Bupropion | No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women. The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose. |
|
| Buprenorphine | No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women. The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose. |
|
| Hydrocodone | No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women. The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose. |
|
| Levetiracetam | No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women. The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose. |
|
| Paroxetine | No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women. The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose. |
|
| Duloxetine | No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women. The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose. |
|
| labetalol | Drug | Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider. |
|
| metformin | Drug | Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider. |
|
| nifedipine | Drug | Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider. |
|
| clindamycin | Drug | Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider. |
|
| oxycodone | Drug | Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider. |
|
| azithromycin | Drug | Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider. |
|
| escitalopram | Drug | Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider. |
|
| sertraline | Drug | Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider. |
|
| ondansetron | Drug | Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider. |
|
| Ciprofloxacin | Drug | Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider. |
|
| Doxycycline | Drug | Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider. |
|
| Levofloxacin | Drug | Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider. |
|
| Methylphenidate | Drug | Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider. |
|
| Sumatriptan | Drug | Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider. |
|
| Citalopram | Drug | Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider. |
|
| Cyclobenzaprine | Drug | Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider. |
|
| Furosemide | Drug | Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider. |
|
| Gabapentin | Drug | Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider. |
|
| Hydrochlorothiazide | Drug | Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider. |
|
| Hydroxyurea | Drug | Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider. |
|
| Rosuvastatin | Drug | Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider. |
|
| Topiramate | Drug | Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider. |
|
| Trazodone | Drug | Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider. |
|
| Valganciclovir | Drug | Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider. |
|
| Venlafaxine | Drug | Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider. |
|
| Verapamil | Drug | Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider. |
|
| Remdesivir | Drug | Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider. |
|
| Anakinra | Drug | Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider. |
|
| Tocilizumab | Drug | Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider. |
|
| Fluvoxamine | Drug | Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider. |
|
| Amoxicillin | Drug | Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider. |
|
| Bupropion | Drug | Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider. |
|
| Duloxetine | Drug | Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider. |
|
| Hydrocodone | Drug | Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider. |
|
| Levetiracetam | Drug | Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider. |
|
| Paroxetine | Drug | Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider. |
|
| Buprenorphine | Drug | Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider. |
|
| Up until 180 days of age |
| SAE | Safety profile of commonly used drugs in infants exposed to drugs in breastmilk is characterized by Serious Adverse Events which are directly related to study procedures and were recorded from participants (infant or mother) at each time point when the study-specific procedure occurred and up until 1 hour after. | Up until 180 days of age |
| ESI | Safety profile of commonly used drugs in infants exposed to drugs in breastmilk is characterized by Events of Special Interest(ESI) which include any pre-specified safety event that could be related to BMS01 drug of interest exposure. ESI's are only assessed for infants and only at study visits from the time the BMS01 DOI was initiated in mother and infant began breast milk feeding through the end of the study / infant age ≤ 180 days | Until the infant becomes 180 days of age |
| Loma Linda University Health | Recruiting | Loma Linda | California | 92354 | United States |
|
| Northwestern University | Completed | Chicago | Illinois | 60611 | United States |
| Ann and Robert H. Lurie Childrens Hospital of Chicago | Recruiting | Chicago | Illinois | 60614 | United States |
|
| Indiana University Health | Completed | Indianapolis | Indiana | 46202 | United States |
| University of Iowa Hospitals and Clinics | Active, not recruiting | Iowa City | Iowa | 52242 | United States |
| Children's Hospital and Clinics - Minneapolis | Recruiting | Minneapolis | Minnesota | 55404 | United States |
|
| University of New Mexico, Health Sciences Center | Completed | Albuquerque | New Mexico | 87131 | United States |
| University of North Carolina Hospital | Completed | Chapel Hill | North Carolina | 27599 | United States |
| Duke University Maternal and Fetal Medicine | Recruiting | Durham | North Carolina | 27705 | United States |
|
| Oregon Health & Science University | Recruiting | Portland | Oregon | 97239 | United States |
|
| Hospital of the University of Pennsylvania Department of Maternal Fetal Medicine | Completed | Philadelphia | Pennsylvania | 19104 | United States |
| University of Pittsburgh School of Medicine | Recruiting | Pittsburgh | Pennsylvania | 15213 | United States |
|
| Texas Tech University Health Sciences Center School of Medicine. | Recruiting | Amarillo | Texas | 79106 | United States |
|
| University of Texas Medical Branch - Galveston | Recruiting | Galveston | Texas | 77555 | United States |
|
| University of Texas Health Science Center at Houston | Recruiting | Houston | Texas | 77030 | United States |
|
| The Women's Hospital of Texas | Recruiting | Houston | Texas | 77054 | United States |
|
| University of Texas Health Science Center | Recruiting | San Antonio | Texas | 78229 | United States |
|
| University of Utah | Recruiting | Salt Lake City | Utah | 84132 | United States |
|
| University of Washington | Completed | Seattle | Washington | 98195-7630 | United States |
| Lawson Health Research Institute | Completed | London | Ontario | N6A 5W9 | Canada |
| Centre Hospitalier Universitaire Sainte-Justine | Completed | Montreal | Quebec | H3T IC5 | Canada |
| ID | Term |
|---|---|
| D014148 | Tranexamic Acid |
| D007741 | Labetalol |
| D008687 | Metformin |
| D009543 | Nifedipine |
| D002981 | Clindamycin |
| D010098 | Oxycodone |
| D017963 | Azithromycin |
| D000089983 | Escitalopram |
| D020280 | Sertraline |
| D017294 | Ondansetron |
| D002939 | Ciprofloxacin |
| D004318 | Doxycycline |
| D064704 | Levofloxacin |
| D008774 | Methylphenidate |
| D018170 | Sumatriptan |
| D015283 | Citalopram |
| C004704 | cyclobenzaprine |
| D005665 | Furosemide |
| D000077206 | Gabapentin |
| D006852 | Hydrochlorothiazide |
| D006918 | Hydroxyurea |
| D000068718 | Rosuvastatin Calcium |
| D000077236 | Topiramate |
| D014196 | Trazodone |
| D000077562 | Valganciclovir |
| D000069470 | Venlafaxine Hydrochloride |
| D014700 | Verapamil |
| C000606551 | remdesivir |
| D053590 | Interleukin 1 Receptor Antagonist Protein |
| C502936 | tocilizumab |
| D016666 | Fluvoxamine |
| D000658 | Amoxicillin |
| D016642 | Bupropion |
| D000068736 | Duloxetine Hydrochloride |
| D006853 | Hydrocodone |
| D000077287 | Levetiracetam |
| D017374 | Paroxetine |
| D002047 | Buprenorphine |
| ID | Term |
|---|---|
| D003509 | Cyclohexanecarboxylic Acids |
| D000146 | Acids, Carbocyclic |
| D002264 | Carboxylic Acids |
| D009930 | Organic Chemicals |
| D004983 | Ethanolamines |
| D000605 | Amino Alcohols |
| D000438 | Alcohols |
| D012457 | Salicylamides |
| D000577 | Amides |
| D000588 | Amines |
| D001645 | Biguanides |
| D006146 | Guanidines |
| D000578 | Amidines |
| D004095 | Dihydropyridines |
| D011725 | Pyridines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D008034 | Lincomycin |
| D055231 | Lincosamides |
| D011759 | Pyrrolidines |
| D006027 | Glycosides |
| D002241 | Carbohydrates |
| D003061 | Codeine |
| D009022 | Morphine Derivatives |
| D009019 | Morphinans |
| D053610 | Opiate Alkaloids |
| D000470 | Alkaloids |
| D006572 | Heterocyclic Compounds, Bridged-Ring |
| D006576 | Heterocyclic Compounds, 4 or More Rings |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D010616 | Phenanthrenes |
| D011084 | Polycyclic Aromatic Hydrocarbons |
| D011083 | Polycyclic Compounds |
| D004917 | Erythromycin |
| D018942 | Macrolides |
| D061065 | Polyketides |
| D007783 | Lactones |
| D011437 | Propylamines |
| D009570 | Nitriles |
| D001572 | Benzofurans |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D015057 | 1-Naphthylamine |
| D009281 | Naphthalenes |
| D006841 | Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D007093 | Imidazoles |
| D001393 | Azoles |
| D002227 | Carbazoles |
| D007211 | Indoles |
| D006575 | Heterocyclic Compounds, 3-Ring |
| D024841 | Fluoroquinolones |
| D042462 | 4-Quinolones |
| D015363 | Quinolones |
| D011804 | Quinolines |
| D013754 | Tetracyclines |
| D009279 | Naphthacenes |
| D015242 | Ofloxacin |
| D010648 | Phenylacetates |
| D010880 | Piperidines |
| D013449 | Sulfonamides |
| D013450 | Sulfones |
| D013457 | Sulfur Compounds |
| D014363 | Tryptamines |
| D013424 | Sulfanilamides |
| D000814 | Aniline Compounds |
| D005680 | gamma-Aminobutyric Acid |
| D000613 | Aminobutyrates |
| D002087 | Butyrates |
| D000144 | Acids, Acyclic |
| D003510 | Cyclohexanes |
| D003516 | Cycloparaffins |
| D006840 | Hydrocarbons, Alicyclic |
| D000596 | Amino Acids |
| D000602 | Amino Acids, Peptides, and Proteins |
| D002740 | Chlorothiazide |
| D001581 | Benzothiadiazines |
| D049971 | Thiazides |
| D014508 | Urea |
| D005464 | Fluorobenzenes |
| D006845 | Hydrocarbons, Fluorinated |
| D006846 | Hydrocarbons, Halogenated |
| D011743 | Pyrimidines |
| D005632 | Fructose |
| D006601 | Hexoses |
| D009005 | Monosaccharides |
| D000073893 | Sugars |
| D007661 | Ketoses |
| D010879 | Piperazines |
| D011728 | Pyridones |
| D015774 | Ganciclovir |
| D000212 | Acyclovir |
| D006147 | Guanine |
| D007042 | Hypoxanthines |
| D011688 | Purinones |
| D011687 | Purines |
| D003511 | Cyclohexanols |
| D000441 | Hexanols |
| D005233 | Fatty Alcohols |
| D010627 | Phenethylamines |
| D005021 | Ethylamines |
| D008055 | Lipids |
| D016207 | Cytokines |
| D036341 | Intercellular Signaling Peptides and Proteins |
| D010455 | Peptides |
| D011506 | Proteins |
| D001685 | Biological Factors |
| D010091 | Oximes |
| D006898 | Hydroxylamines |
| D000667 | Ampicillin |
| D010400 | Penicillin G |
| D010406 | Penicillins |
| D047090 | beta-Lactams |
| D007769 | Lactams |
| D011427 | Propiophenones |
| D007659 | Ketones |
| D013876 | Thiophenes |
| D000081 | Acetamides |
| D000085 | Acetates |
| D011760 | Pyrrolidinones |
Not provided
Not provided